Clinical Trial Update: Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent [Phase 4]

View source ↗

Summary

A Phase 4 trial compared cabazitaxel to switching to another AR-targeted agent (enzalutamide or abiraterone) in metastatic castration-resistant prostate cancer …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Abiraterone (abiraterone)
• Cabazitaxel (cabazitaxel)
• Enzalutamide (enzalutamide)

Snippet

Sponsor: Sanofi | Conditions: Prostate Cancer Metastatic | Phase 4 | Status: COMPLETED | Results posted: 2022-02-14